EDGAR·FLOW

Lipocine Inc. — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Lipocine dosed the first participant in BLOOM, a Phase 3 placebo-controlled study of LPCN 1154 (oral brexanolone) for postpartum depression, enrolling ~120 participants. The 48-hour at-home oral treatment study incorporates FDA feedback and learnings from a prior failed Phase 3 trial, with topline results expected in H2 2027. FDA confirmed the NDA submission package is complete except for a single positive, well-controlled Phase 3 trial, which BLOOM is designed to provide.
Why this rating

For a $16.4M company, advancing a lead program toward NDA submission is material. Prior Phase 3 failure, regulatory pathway clarity, and 18-month de-risking window carry real stock-relevant weight, but clinical trial success is uncertain and capital-intensive.

Tradability signal
NO TRADE

No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.11% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$1.67
+10 min · unknown
$1.63 ▼ 2.40%
+30 min · unknown
$1.61 ▼ 3.71%
+1 hr · unknown
$1.61 ▼ 3.59%
+4 hrs · unknown
$1.63 ▼ 2.40%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ LPCN · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.